Table 1.
In vitro efficacy data for PIKfyve inhibitors against SARS-CoV-2 in VeroE6 and A549/hACE2 cells.
| Compound | VeroE6 cells | A549/hACE2 | ||||
|---|---|---|---|---|---|---|
| IC50 (nM) | CC50 (nM) | SI | IC50 (nM) | CC50 (nM) | SI | |
| Apilimod | 10.05 | >5000 | >497.51 | 3.23 | >5000 | >1547.99 |
| WX8 | 110.50 | >5000 | >45.25 | 22.62 | >5000 | >221.04 |
| NDF | 639.00 | >5000 | >7.82 | 9.39 | >5000 | >532.48 |
| WWL | 2110 | >5000 | >2.37 | 171.90 | >5000 | >29.09 |
| XB6 | 1205 | >5000 | >4.15 | 191.00 | >5000 | >26.18 |
| Remdesivir | 546.5 | >5000 | >9.15 | 155.85 | >5000 | >32.08 |
IC50 half-maximal inhibitory concentration, CC50 half-maximal cytotoxic concentration, SI selectivity index.